Comparative and combined effectiveness of innovative therapies in cancer: a literature review

Geldof, Tine; Rawal, Smita; Dyck, Walter Van; Huys, Isabelle

doi:10.2217/cer-2018-0131

Cited by 4 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination therapy is a central concept in modern medicine, and multi-agent therapies have been a mainstay of cancer treatment [ 63 , 64 , 65 , 66 , 67 ]. When using combination therapy, interactions may be beneficial (additive or synergistic), neutral or harmful (by increasing toxicity and/or decreasing efficacy) [ 63 , 68 ].…”

Section: Discussionmentioning

confidence: 99%

Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro

Abrahams,

Gerber,

Hiss

2024

IJMS

View full text Add to dashboard Cite

The role of the epidermal growth factor receptor (EGFR) in tumor progression and survival is often underplayed. Its expression and/or dysregulation is associated with disease advancement and poor patient outcome as well as drug resistance in breast cancer. EGFR is often overexpressed in breast cancer and particularly triple-negative breast cancer (TNBC), which currently lacks molecular targets. We examined the synergistic potential of an EGFR inhibitor (EGFRi) in combination with doxorubicin (Dox) in estrogen-positive (ER+) MCF-7 and MDA-MB-231 TNBC cell lines. The exposure of MDA-MB-231 and MCF-7 to EGFRi produced an IC50s of 6.03 µM and 3.96 µM, respectively. Dox induced MDA-MB-231 (IC50 9.67 µM) and MCF-7 (IC50 1.4 µM) cytotoxicity. Combinations of EGFRi-Dox significantly reduced the IC50 in MCF-7 (0.46 µM) and MBA-MB 231 (0.01 µM). Synergistic drug interactions in both cell lines were confirmed using the Bliss independence model. Pro-apoptotic Caspase-3/7 activation occurred in MCF-7 at 0.1–10 µM of EGFRi and Dox single treatments, whilst 1 μM Dox yielded a more potent effect on MDA-MB-231. EGFRi and Dox individually and in combination downregulated the EGFR gene expression in MCF-7 and MDA-MB-231 (p < 0.001). This study demonstrates EGFRi’s potential for eliciting synergistic interactions with Dox, causing enhanced growth inhibition, apoptosis induction, and downregulation of EGFR in both cell lines.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro

Abrahams,

Gerber,

Hiss

2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Based on the most recent statistical report, about 5370 new occurrences, and 1670 deaths each day are expected during 2023 in the United States ( 1 ). Due to high morbidity and mortality rates, tremendous efforts have been devoted to the search for anticancer modalities ( 2 , 3 ). Although advances have been made in traditional therapeutic methods, including surgery, chemotherapy, and radiotherapy, the reliable cure is still limited.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities

Wang,

Pei,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Since the successful application of messenger RNA (mRNA) vaccines in preventing COVID-19, researchers have been striving to develop mRNA vaccines for clinical use, including those exploited for anti-tumor therapy. mRNA cancer vaccines have emerged as a promising novel approach to cancer immunotherapy, offering high specificity, better efficacy, and fewer side effects compared to traditional treatments. Multiple therapeutic mRNA cancer vaccines are being evaluated in preclinical and clinical trials, with promising early-phase results. However, the development of these vaccines faces various challenges, such as tumor heterogeneity, an immunosuppressive tumor microenvironment, and practical obstacles like vaccine administration methods and evaluation systems for clinical application. To address these challenges, we highlight recent advances from preclinical studies and clinical trials that provide insight into identifying obstacles associated with mRNA cancer vaccines and discuss potential strategies to overcome them. In the future, it is crucial to approach the development of mRNA cancer vaccines with caution and diligence while promoting innovation to overcome existing barriers. A delicate balance between opportunities and challenges will help guide the progress of this promising field towards its full potential.

show abstract

Nanofibers for the Management of Allergic Airway Disease

Sharma,

Arora,

Chaudhary

et al. 2024

Understanding Allergic Airway Diseases

View full text Add to dashboard Cite

Comparative and combined effectiveness of innovative therapies in cancer: a literature review

Cited by 4 publications

References 72 publications

Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro

Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro

Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities

Nanofibers for the Management of Allergic Airway Disease

Contact Info

Product

Resources

About